GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Rating of “Buy” from Brokerages

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been given a consensus rating of “Buy” by the seven analysts that are covering the company, MarketBeat reports. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $14.20.

A number of equities analysts have issued reports on the stock. Alliance Global Partners began coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective on the stock. Noble Financial upped their price target on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, August 19th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a research report on Friday, November 15th. Finally, D. Boral Capital restated a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a report on Tuesday, November 19th.

GeoVax Labs Stock Performance

GOVX opened at $2.19 on Friday. The stock’s 50 day simple moving average is $2.31 and its 200 day simple moving average is $2.70. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.38. The firm had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same quarter in the prior year, the business posted ($4.80) EPS. Analysts expect that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC bought a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs at the end of the most recent quarter. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.